zenodoopen
The Origin and Clinical Benefit of First-in-Class Drugs that entered the French market between 2008 and 2018
<p>This file contains a data set of 135 First-in-class medicines that entered the French market between 2008 to 2018. For each drug we present data on provenance (inventor of the drug) and clinical benefit grading by Haute Autorité de Santé (HAS) and Prescrire. A legend on matching clinical grading scale can be found on tab 3 of the document.</p>
ShareScore
40/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 4
- Access
- 16
- Reuse readiness
- 8
- Engagement
- 4